Search Results - "Juan, Cundom"

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study by Oh, Do-Youn, He, Aiwu Ruth, Bouattour, Mohamed, Okusaka, Takuji, Qin, Shukui, Chen, Li-Tzong, Kitano, Masayuki, Lee, Choong-Kun, Kim, Jin Won, Chen, Ming-Huang, Suksombooncharoen, Thatthan, Ikeda, Masafumi, Lee, Myung Ah, Chen, Jen-Shi, Potemski, Piotr, Burris, 3rd, Howard A, Ostwal, Vikas, Tanasanvimon, Suebpong, Morizane, Chigusa, Zaucha, Renata E, McNamara, Mairéad G, Avallone, Antonio, Cundom, Juan E, Breder, Valeriy, Tan, Benjamin, Shimizu, Satoshi, Tougeron, David, Evesque, Ludovic, Petrova, Mila, Zhen, David B, Gillmore, Roopinder, Gupta, Vineet Govinda, Dayyani, Farshid, Park, Joon Oh, Buchschacher, Jr, Gary L, Rey, Felipe, Kim, Hyosung, Wang, Julie, Morgan, Claire, Rokutanda, Nana, Żotkiewicz, Magdalena, Vogel, Arndt, Valle, Juan W

“…In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus…”
Get more information

Real‑world evaluation of molecular testing and treatment patterns for EGFR mutations in non‑small cell lung cancer in Latin America by Claudio, Martin, Mauricio, Cuello, Olga, Barajas, Gonzalo, Recondo, Sandra, Aruachan, Herman, Perroud, Susana, Sena, Carlos, Bonilla, Francisco, Orlandi, Susana, Berutti, Virginia, Garcia, Alvaro, Gomez, Ernesto, Korbenfeld, Maycos, Zapata, Juan, Cundom, Eric, Orellana, Susana, Goncalves, Florencia, Reinhold

“…Lung cancer is a leading cause of cancer-related deaths in Latin America, with non-small cell lung cancer (NSCLC) being the most prevalent. The current study…”
Get full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial by Rha, Sun Young, Oh, Do-Youn, Yañez, Patricio, Bai, Yuxian, Ryu, Min-Hee, Lee, Jeeyun, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Shiu, Kai-Keen, Fernández, Manuel González, Li, Jin, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Qin, Shukui, Luo, Suxia, Pan, Hongming, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, Wyrwicz, Lucjan S

“…PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of…”
Get full text

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial by Dzienis, Marcin, Cundom, Juan, Fuentes, Christian Sebastian, Spreafico, Anna, Nordlinger, Melanie, Pastor, Andrea Viviana, Alesi, Erin, Neki, Anterpreet, Fung, Andrea S, Figueiredo Lima, Iane Pinto, Oppelt, Peter, da Cunha Junior, Geraldo Felicio, Burtness, Barbara, Franke, Fabio Andre, Tseng, Jennifer E, Joshi, Abhishek, McCarthy, Joy, Swaby, Ramona, Sidi, Yulia, Gumuscu, Burak, Naicker, Niroshini, de Castro, Jr, Gilberto

“…Standard-of-care first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is pembrolizumab plus platinum and…”
Get full text

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study by Kawazoe, Akihito, Xu, Rui-Hua, García-Alfonso, Pilar, Passhak, Maria, Teng, Hao-Wei, Shergill, Ardaman, Gumus, Mahmut, Qvortrup, Camilla, Stintzing, Sebastian, Towns, Kathryn, Kim, Tae Won, Shiu, Kai Keen, Cundom, Juan, Ananda, Sumitra, Lebedinets, Andrey, Fu, Rong, Jain, Rishi, Adelberg, David, Heinemann, Volker, Yoshino, Takayuki, Elez, Elena

“…Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib…”
Get full text

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 by Oh, Do-Youn, He, Aiwu Ruth, Qin, Shukui, Chen, Li-Tzong, Okusaka, Takuji, Vogel, Arndt, Kim, Jin Won, Suksombooncharoen, Thatthan, Lee, Myung Ah, Kitano, Masayuki, Burris III, Howard A., Bouattour, Mohamed, Tanasanvimon, Suebpong, Zaucha, Renata, Avallone, Antonio, Cundom, Juan, Rokutanda, Nana, Xiong, Julia, Cohen, Gordon, Valle, Juan W.

“…Abstract only 378 Background: BTC is a rare, heterogenous cancer with poor prognosis. Reports on immunogenic features of BTC suggest checkpoint inhibition may…”
Get full text

Liver Transplantation in the Treatment of Neuroendocrine Metastatic Tumors: Our Experience by Gondolesi, Gabriel, Pattin, Francisco F, Rubio, Santiago S, Benitez, Marcela M, Cundom, Juan J, Schelotto, Pablo P Barros, Descalzi, Valeria V

“…INTRODUCTIONNeuroendocrine tumors (NET) are a heterogeneous group of malignant gastrointestinal tumors. Usually they exhibit functional or non-functional but…”
Get full text

Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer by Oh, Do-Youn, He, Aiwu Ruth, Qin, Shukui, Chen, Li-Tzong, Okusaka, Takuji, Vogel, Arndt, Kim, Jin Won, Suksombooncharoen, Thatthan, Lee, Myung Ah, Kitano, Masayuki, Burris, Howard, Bouattour, Mohamed, Tanasanvimon, Suebpong, McNamara, Mairead G, Zaucha, Renata, Avallone, Antonio, Tan, Benjamin, Cundom, Juan, Lee, Choong-Kun, Takahashi, Hidenori, Ikeda, Masafumi, Chen, Jen-Shi, Wang, Julie, Makowsky, Mallory, Rokutanda, Nana, Żotkiewicz, Magdalena, Kurland, John F, Cohen, Gordon, Valle, Juan W

“…This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and…”
Get full text

Cutaneous metastasis of lung cancer by Rotondaro, Julio C, Bogiaizian, Alejo, Gomez Wolffe, Florencia, Cundom, Juan, Gazzi, Carla

Get more information